Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness
-
- Sara Guerreiro Castro
- Autoimmune Diseases Unit, Internal Medicine 7.2 Dept, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal
-
- David A. Isenberg
- Centre for Rheumatology, University College London, Room 424, 4th Floor Rayne Building, 5 University Street, London WC1E 6JF, UK
説明
<jats:p> Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials. </jats:p>
収録刊行物
-
- Therapeutic Advances in Musculoskeletal Disease
-
Therapeutic Advances in Musculoskeletal Disease 9 (3), 75-85, 2017-03
SAGE Publications
